William Blair analyst Myles Minter has maintained their bullish stance on DNTH stock, giving a Buy rating on September 5.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Myles Minter has given his Buy rating due to a combination of factors surrounding Dianthus Therapeutics’ recent clinical advancements. The company released promising Phase II data for its C1s inhibitor, claseprubart, in the treatment of generalized myasthenia gravis (gMG). The efficacy results from the low dose of claseprubart, which will proceed to a Phase III trial, appear competitive with existing treatments, offering advantages in dosing convenience and potentially superior safety.
Minter’s confidence is further bolstered by the statistically significant improvements observed in the MaGic trial, which demonstrated notable efficacy in both dosing arms without the need for data pooling. Additionally, the potential for claseprubart to be effective in other autoimmune neurology conditions, such as CIDP and MMN, where there is less market competition, adds to the positive outlook. These factors collectively enhance the investment appeal of Dianthus Therapeutics, justifying the Buy rating.
In another report released on September 5, Guggenheim also reiterated a Buy rating on the stock with a $92.00 price target.